SCENESSE® applied under five-year Veterans Affairs contract
CLINUVEL has been awarded a five-year contract by the U.S. Department of...
Read MoreCLINUVEL secures IP for melanocortins to treat central nervous system disorders
CLINUVEL has secured a family of patents and patent applications relating to...
Read MoreNotification regarding unquoted securities
CLINUVEL today released a notification regarding unquoted securities.
Read MoreTwo grounds of Appeal upheld by NICE Panel
In an announcement released today, CLINUVEL provided an updated on the outcome...
Read MoreNews Kommuniqué III
Melbourne, Australia, 26 June 2023 ASX: CUV XETRA-DAX: UR9 Level 1 ADR:...
Read MoreNotification of cessation of securities
CLINUVEL today released a notification regarding cessation of securities.
Read MoreTwilight Event - Briefing
CLINUVEL presented during a Twilight Briefing, after the close of market yesterday....
Read MoreChange of Director’s Interest Notice
CLINUVEL today released a notification regarding a change of Director’s interest.
Read MoreNews Communiqué III
CLINUVEL’s News Communiqué III reviews the Company’s trajectory, and underlying reasons to...
Read MoreCLINUVEL Bulletin Edition 01
The first in a new series providing updates on CLINUVEL's Brand Architecture,...
Read MoreCLINUVEL escalates PRÉNUMBRA® to moderate/severe stroke patients
CLINUVEL announced the escalation of PRÉNUMBRA® Instant to moderate-to-severe and severe stroke...
Read MoreExpansion of CLINUVEL’s global porphyria programs
CLINUVEL today released an update on the use its drug SCENESSE® (afamelanotide...
Read MoreNews Kommuniqué II
Melbourne, Australia, 12 January 2023 ASX: CUV XETRA-DAX: UR9 Level 1 ADR:...
Read MoreNews Communiqué I - Ms Cristina Ramos
Introducing CLINUVEL’s next Intriguing Personality (CUVIP), Ms Cristina Ramos.
Read More